Market Access 2020: Understanding US Payer Expectations
How Much Longer For Biopharma’s Habitual Hamlet Fixation: To Risk Or Not To Risk?
Big pharma is facing a difficult US competitive landscape as its traditional customers realign to build their own redoubts of size, scale and reach.
You may also be interested in...
Bayer’s ambitious campaign to reposition itself as a global leader in two complementary fields – health and nutrition – will face its toughest test in the US, with its highly litigious approach to product liability and a tendency to target pharmaceuticals as the source of the health system’s affordability and access problems.
Insights from Gates Medical Research Institute CEO Dr. Penny Heaton.
In Vivo visits Gates Medical Research Institute CEO Dr. Penny Heaton to review its first pipeline of drugs and vaccines to attack four of the world’s biggest killers: TB, malaria, enteric diseases and other conditions affecting maternal, newborn and child health.